There are currently no generic Rescriptor (delavirdine mesylate) products available on the market. It's possible that a generic version could be introduced as soon as 2019, when the next patent is set to expire. Keep in mind that delavirdine sulfate is the active ingredient in Rescriptor, but is not the same as generic Rescriptor.
Generic Rescriptor: An Overview
Rescriptor® (delavirdine mesylate) is a prescription medication for HIV and AIDS. It is part of a group of medications known as non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is approved to be used only in combination with other HIV medications.
Rescriptor is made by Pfizer, Inc. It is currently under the protection of patents that prevent any generic Rescriptor from being manufactured in the United States.
When Will Generic Rescriptor Be Available?
The first patent for Rescriptor expired in October 2013, yet no generic versions are available. This suggests that another patent, set to expire in June 2019, may still be providing protection against generic competition. This is the earliest possible date that a generic version of the drug could become available.
However, other circumstances could come up to extend the exclusivity period of the drug beyond 2019. This could include such things as other patents for specific Rescriptor uses or lawsuits. Once all the patents expire, several companies will likely begin manufacturing a generic Rescriptor drug.
Is Delavirdine the Same as Generic Rescriptor?
No -- delavirdine is the active ingredient in Rescriptor, but is not a generic version of it. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Rescriptor [package insert]. New York, NY: Pfizer, Inc.;2006 June.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed December 3, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click